XWXiLiang Wang

XiLiang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


XiLiang Wang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Li Xing

    Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China

    3 shared publications
  • Peng Li

    Academy of Military Medical Sciences

    2 shared publications
  • Bing Ni

    Department of Pathophysiology, College of High Altitude Military Medicine, Army Medical University (Third Military Medical University), Chongqing, China

    1 shared publication
  • Chong Tang

    Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China

    1 shared publication
  • Chong Tang

    Department of Immunology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 20 Dong-Da Street, Fengtai District, Beijing 100071, China

    1 shared publication
  • De-Yan Luo

    1 shared publication

Latest Publications

  • Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine

    by Penghui Yang, Li Xing, Chong Tang, Weihong Jia, Zhongpeng Zhao, Kun Liu, Xiao Gao, Xiliang Wang

    The novel influenza A (H1N1) 2009 virus has emerged to cause the first pandemic of the twenty-first century. Disease outbreaks caused by the influenza A (H1N1) virus have prompted concerns about the potential for a pandemic and have driven the development of vaccines against this subtype of influenza A. In this study, we developed a monovalent influenza A (H1N1) split vaccine and evaluated its effects in BALB/c mice. Mice were immunized subcutaneously with 2 doses of the vaccine containing hemagglutinin (HA) alone or HA plus an aluminum hydroxide (Al(OH)3) adjuvant. Immunization with varying doses of HA (3.75, 7.5, 15, 30, 45 or 60 µg) was performed to induce the production of neutralizing antibodies. The vaccine elicited strong hemagglutination inhibition (HI) and microneutralization, and addition of the adjuvant augmented the antibody response. A preliminary safety evaluation showed that the vaccine was not toxic at large doses (0.5 ml containing 60 µg HA+600 µg Al(OH)3 or 60 µg HA). Moreover, the vaccine was found to be safe at a dose of 120 µg HA+1200 µg Al(OH)3 or 120 µg HA in 1.0 ml in rats. In conclusion, the present study provides support for the clinical evaluation of influenza A (H1N1) vaccination as a public health intervention to mitigate a possible pandemic. Additionally, our findings support the further evaluation of the vaccine used in this study in primates or humans.


  • Development and Identification of a Live Attenuated Influenza B Virus Vaccine Candidate*

    by Peng-Hui Yang, Wen-Qi An, Xin-Fu Shi, Yue-Qiang Duan, De-Yan Luo, Peng-Fei Zhang, Chong Tang, Li Xing, Yu-Jing Zhang, Xiu-Fan Liu, et al.

  • Immunological dynamics in response to two anthrax vaccines in mice

    by Jin Lü, Rui He, Mei Dong, LiangYan Zhang, XiLiang Wang

    In order to understand the variation of humoral and cellular immune responses to A16R live spore and AVA vaccine and to identify efficient immunological parameters for the early evaluation of post immunization in mice, we dynamically monitored the antibody production and cellular responses after the vaccination of Balb/C mice with the anthrax vaccines. The results show that both anti-AVA and anti-Spore antibodies were detectable in the A16R live spore vaccinated group while high titers of anti-AVA antibodies but not anti-Spore antibodies existed in the AVA-immunized group. IgG1 and IgG2 were the major subtypes of IgG in both of the two groups. However, the IgG2a level was significantly higher in the A16R group than in the AVA group. At the cellular level, responses of antigen-specific TH2, TH1 and plasma cells were detected. The peripheral TH2 responses could be seen on day 5 after vaccination, and remained at a high level throughout the experiment (from day 5 post primary immunization to day 60 post the tertiary immunization); the TH1 responses to A16R vaccine appeared on day 5, while the responses to AVA could only be detected by day 7 after the secondary immunization; a low level of TH1 responses could be observed at the end of the experiment. Antigen-specific plasma cells could be found in the peripheral blood of both the immunized groups, however, the responses in the A16R group appeared earlier, lasted longer, and shown an ascending tendency until the end of the experiment when the plasma cell responses in the AVA group were reduced to a very low level. The results suggest that the multiple antigen containing A16R live spore vaccine induces better immune responses than AVA. Combined with serum antibody titers, TH2, TH1 and plasma cell responses could be used as immunological parameters for the evaluation of vaccine efficacy. These findings may afford new insight into the early evaluation of vaccination as well as being a powerful strategy for vaccine development.


  • Protective Immunity Elicited by a Divalent DNA Vaccine Encoding Both the L7/L12 and Omp16 Genes ofBrucella abortusin BALB/c Mice

    by Deyan Luo, Bing Ni, Peng Li, Wei Shi, Songle Zhang, Yue Han, Liwei Mao, Yangdong He, Yuzhang Wu, Xiliang Wang

    This study was designed to evaluate the immunogenicity and the protective efficacy of a divalent fusion DNA vaccine encoding both theBrucella abortusL7/L12 protein (ribosomal protein) and Omp16 protein (outer membrane lipoprotein), designated pcDNA3.1-L7/L12-Omp16. Intramuscular injection of this divalent DNA vaccine into BALB/c mice elicited markedly both humoral and cellular immune responses. The specific antibodies exhibited a dominance of immunoglobulin G2a (IgG2a) over IgG1. In addition, the dual-gene DNA vaccine elicited a strong T-cell proliferative response and induced a large amount of gamma interferon-producing T cells upon restimulation in vitro with recombinant fusion protein L7/L12-Omp16, suggesting the induction of a typical T-helper-1-dominated immune response in vivo. This divalent DNA vaccine could also induce a significant level of protection against challenge with the virulent strainB. abortus544 in BALB/c mice. Furthermore, the protection level induced by the divalent DNA vaccine was significantly higher than that induced by the univalent DNA vaccines pcDNA3.1-L7/L12 or pcDNA3.1-Omp16. Taken together, the results of this study verify for the first time that the Omp16 gene can be a candidate target for a DNA vaccine against brucellosis. Additionally, a divalent genetic vaccine based on the L7/L12 and Omp16 genes can elicit a stronger cellular immune response and better immunoprotection than the relevant univalent vaccines can.